Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Shares Slide 11 Percent on Earnings Restatement and Delisting Notice

NEW YORK, April 7 (GenomeWeb News) - Shares of Orchid Cellmark were down 11.21 percent, or $.60, at $4.75 in mid-afternoon trading after the company reported that it will restate its earnings for the second and third quarters of 2005, and that it has received a delisting warning from the Nasdaq exchange for failing to file a financial statement on time.

 

As GenomeWeb News reported this morning, the earnings restatements were traced to 163,259 shares of Lifecodes, which Orchid acquired in December 2001, which were valued at $1.6 million and that should have been recorded at the settlement date as a non-operating gain and an acquisition of treasure stock, according to Orchid.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.